retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 (LY3437943): of Action and Research Overview Triple Agonism Based Therapies for
Description
Third, GIP receptor activation has not been shown to cause proliferation and anti-apoptosis
AP events were predominantly reported for unknown indications (53.8%) and T2DM (43.0%)
How does Blue Cross manage and combat unnecessary costs of GLP-1 drugs
Clinical Trial Evidence: Landmark cardiovascular outcome trials (CVOTs) like the SELECT trial (for semaglutide) have shown a significant reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death
JAMA 331 , 952953 (2024)
17,67,68 The mechanism behind atherosclerosis prevention is not completely clear
